Please ensure Javascript is enabled for purposes of website accessibility

Before You Buy Zomedica Stock, Stop and Consider These 3 Things

By Cory Renauer - Mar 23, 2021 at 6:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a few things you should know before risking your hard-earned money on this stock.

In case you haven't been paying attention, pets are responsible for a growing portion of the economy right now. Pandemic-fueled isolation has accelerated a long-running trend of increasing pet adoption, and soaring demand for veterinary services.

Anyone that's taken their fur baby to the vet for a serious condition knows diagnostic services can be expensive, and slow. That's why everyone's been talking about Zomedica (ZOM -0.25%) and its recently launched diagnostic tool for adrenal gland and thyroid gland conditions. 

A team of healthcare professionals is gathered around a table in a conference room.

Image source: Getty Images.

Zomedica's Truforma system isn't much bigger than a toaster and it can produce results on the fly. Demand for this innovative solution could drive sales of the diagnostic tool and the company's stock price through the roof over the next several quarters.

Before you add any Zomedica shares to your portfolio, though, there are a few things about this company that you should consider first.

1. Turning the corner

Up until March 16, Zomedica was a development-stage company with research and development expenses but no source of revenue to pay them. 

To fuel the commercial launch of its Truforma system Zomedica raised an impressive $217 million this year, bringing its cash balance to a healthy $278 million as of Feb. 26. That looks like a healthy cushion for a company that lost just $17 million last year, but that was while it was a developmental-stage company with less than two dozen employees.

Hiring a sales staff to launch Truforma will boost expenses and even Zomedica doesn't know how expensive turning the commercial-stage corner will become. The company didn't provide any forward guidance with its fourth-quarter earnings report. 

2. Validation data?

Last November, Zomedica initiated validation of its assays after reporting successful verification study results. When the company ran cortisol and thyroid hormone tests on equipment from Seimens, the results fell in line with those reported by Truforma. When Zomedica reported 2021 earnings in February, though, validation efforts for the company's tests were still under way.

The initial launch of the Truforma platform could be extra challenging because veterinarians still can't be certain the results Truforma produces will be as accurate as results they're used to receiving from outside laboratories. It might be a good idea to wait for that validation data, or at least wait for sales growth that indicates veterinarians aren't bothered by its absence. 

3. Big expectations

Investors expecting great things from Zomedica have driven the stock's market cap up to a whopping $1.9 billion at recent prices. That's an awfully big valuation for a company that has only just started recording sales. Point-of-care diagnostic products are increasingly popular with doctors that treat people, but nobody's really tried to market them to veterinarians yet. 

Zomedica's headquartered in Michigan, but its first customer was the president of a giant animal care hospital in New York. If sales of Truforma are limited to giant operations like this one, Zomedica won't have a chance to live up to the expectations the stock market has placed on it. 

Stay patient

Zomedica's Truforma is the first and only diagnostic platform that relies on bulk-acoustic wave technology. While this could be a huge advantage, new diagnostic products that excite investors before their commercial launch end up disappointing them more often than they succeed.

It doesn't cost anything to let a hot opportunity pass you by, but you could suffer heavy losses if Zomedica doesn't begin reporting impressive sales over the next several quarters. Before you risk your hard-earned money, it's probably best to wait for signs of a successful launch in the company's upcoming earnings reports.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
$0.24 (-0.25%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.